Source-grounded facts extracted from Arcadia Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Arcadia Biosciences, Inc. engaged Ramirez Jimenez International CPAs as its auditor.
“the Audit Committee approved the engagement of Ramirez Jimenez International CPAs (“RJI”), effective immediately upon the dismissal of Deloitte, as the Company’s independent registered public accounting firm”
Arcadia Biosciences, Inc. dismissed Deloitte & Touche LLP as its auditor.
“dismissed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm.”
Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
“On March 26, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025.”
Arcadia Biosciences, Inc. entered into Inducement Letters with Participating Holders valued at Aggregate gross proceeds of approximately $2.1 million from exercise of Existing Options (effective 2026-01-09).
“On January 9, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with certain investors (the “Participating Holders”) pursuant to which such Participating Holders agreed to exercise certain outstanding preferred investment options to purchase an aggregate of 808,595 shares of the Company’s common stock ("Common Stock").”
Arcadia Biosciences, Inc. terminated Securities Exchange Agreement with Roosevelt Resources, LP (effective 2025-12-24).
“On December 24, 2025, the Company received a notice from Roosevelt indicating that it was terminating the Exchange Agreement with immediate effect pursuant to the Termination Provisions”
Thomas J. Schaefer was appointed as Class I Director at Arcadia Biosciences, Inc..
“On August 1, 2024, the board of directors (the “Board”) of Arcadia Biosciences, Inc. (“Arcadia” or the “Company”) appointed Thomas J. Schaefer, Arcadia’s current president and chief executive officer, to serve as a Class I director of the Company.”
Mark Kawakami was appointed as chief financial officer at Arcadia Biosciences, Inc..
“Arcadia’s board of directors appointed Mark Kawakami as Arcadia’s new chief financial officer to succeed Mr. Schaefer, effective as of July 5, 2024.”
Thomas J. Schaefer was appointed as president and chief executive officer at Arcadia Biosciences, Inc..
“Arcadia’s board of directors appointed Thomas J. Schaefer, Arcadia’s current chief financial officer, to the position of president and chief executive officer of Arcadia, effective as of July 5, 2024.”
Stanley Jacot, Jr. resigned as president, chief executive officer and director at Arcadia Biosciences, Inc..
“Mr. Jacot resigned as Arcadia’s president, chief executive officer and director.”
Arcadia Biosciences, Inc. completed a disposition involving Pioneer Hi-Bred International, Inc. for $4,000,000 in cash (closed 2024-05-13).
“worked to introgress the resistant starch durum wheat trait into elite germplasm lines. As consideration for the sale and license of Purchased Assets, Pioneer paid to Arcadia $4,000,000 in cash, which consideration was determined based on negotiations between the parties. The Agreement includes a number customary provisions addressing matters such as closing”
Arcadia Biosciences, Inc. entered into Asset Purchase Agreement with Pioneer Hi-Bred International, Inc. valued at $4,000,000 in cash (effective 2024-05-13).
“On May 13, 2024, Arcadia Biosciences, Inc. (“Arcadia”) entered into an Asset Purchase Agreement (the “Agreement”) with Pioneer Hi-Bred International, Inc. (“Pioneer”), an indirect, wholly-owned subsidiary of Corteva, Inc., pursuant to which on May 13, 2024 Arcadia sold or licensed to Pioneer certain patent and related rights associated with Arcadia’s resistant starch durum wheat trait (“Purchased Assets”).”
Arcadia Biosciences, Inc. reported financial results for the first quarter ended March 31, 2024.
“On May 9, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 31, 2024.”
Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 28, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.